Options for Patients With Lung Cancer and Genetic Alterations
April 11, 2020 06:00pm
By Luis E. Raez, MD
Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.
Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, discusses the importance of molecular testing in patients with nonsquamous nonsmall cell lung cancer (NSCLC) during the World Conference on Lung Cancer (WCLC) in Toronto, Canada.
In this patient population, Barlesi recommends testing for at least 4 biomarkers, including EGFR, ALK, ROS1, and BRAF. He says there are now clear signs of efficacy with additional biomarkers, as well.
Barlesi says results were presented at this year’s WCLC meeting for patients withRET, NTRK, and TRK rearrangements. The field continues to grow rapidly with many approved drugs, as well some that have received a breakthroughdesignation from the FDA.